Research funder · United States
Michael J. Fox Foundation for Parkinson's Research
Non-profit organization in the USA
- Grants since 2016
- 1 275
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 3 085
- Funded works, all time
- 6 716
Grants
2021 · research · PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development
Development of a New Class of PET Tracers for Imaging Tau and Alpha-synuclein
Muralidhar Reddy Moola · Anven Biosciences Inc.
2021 · research · Aligning Science Across Parkinson's
Dual Role of Neural Activity in Parkinson’s Disease
William C. Mobley · University of California San Diego
2021 · research · Analysis of Patient-Reported Outcomes from Fox Insight
Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease
Lasse Pihlstrøm · Oslo University Hospital
2021 · research · Target Advancement Program
Developing a Protein Quality Control Mechanism as a Novel Therapy for Parkinson’s Disease
Xiaolu Yang · University of Pennsylvania
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease
Alan J. Cross · Psy Therapeutics, Inc
2021 · research · Therapeutic Pipeline Program
Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway
Paul Thompson · Mission Therapeutics
2021 · research · Expanding Biological Understanding of PD
Dissecting the Role of GBA1 and LRRK2 in Regulating the Formation of Lewy Bodies
Hilal A. Lashuel · École Polytechnique Fédérale de Lausanne
2021 · research · Aligning Science Across Parkinson's
Redefining Parkinson’s Disease Pathophysiology Mechanisms in the Context of Heterogeneous Substantia Nigra Neuron Subtypes
William C. Mobley · University of California San Diego
2021 · research · Summer 2021 RFP: Expanding Biological Understanding of PD
Assessment of LRRK2 Activity and Neurodegeneration Markers in Postmortem Brain Samples of Idiopathic and LRRK2-associated Parkinson’s Disease
Thomas J Montine · Stanford University
2021 · research · Aligning Science Across Parkinson's
Mapping the Modulatory Landscape Governing Striatal Dopamine Signaling and Its Dysregulation in Parkinson’s Disease
William C. Mobley · University of California San Diego
2021 · research · Research Grant
Gut Inflammation and Microbial Imbalance in Parkinson’s Disease
Lana Chahine · University of Pittsburgh
2021 · research · Therapeutic Pipeline Program
Novel Inhibitors of Protein Aggregation as Potential Therapeutics for Parkinson’s Disease
Lorraine V. Kalia · University of Toronto
2021 · research · Therapeutic Pipeline Program
Understand Me for Life: An Intelligibility App for Parkinson's Disease
Gemma Moya-Galé · Columbia University
2021 · research · Aligning Science Across Parkinson's
Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
William C. Mobley · University of California San Diego
2021 · research · Environmental Risk Factors
Environmental Risk Factors for Parkinson’s Disease in a Prospective Veteran Cohort
Samuel M. Goldman · University of California, San Francisco
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
Arianna Bellucci · University of Brescia
2021 · research · Biomarkers
Autoimmune Targeting of Mitochondria as a New Biomarker for Parkinson’s Disease
Diana Matheoud · University Of Montréal, Chum Research Center
2021 · research · Priority Biology
Gene Expression Changes Induced by Alpha-Synuclein
Richard Wade-Martins · University of Oxford
2021 · research · Research Grant
Bipolar Disorder and Parkinson’s Disease
Caroline Tanner · University of California, San Francisco
2021 · research · Target Advancement Program
Exploring the Role of FAIM, an Inhibitor of Cell Death, in Parkinson’s Disease
Hiroaki Kaku · Western Michigan University
2021 · research · Priority Biology
Efficacy of PRKN Gene Delivery toward Mitigation of Alpha-synuclein-induced Degeneration
Jennifer A. Johnston · Nysnobio
2021 · research · Therapeutic Pipeline Program
Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease
Neil Derek Miller · Nrg Therapeutics Ltd
2021 · research · Research Grant
Genotyping of Lymphoblastoid Cell Lines from Familial and Sporadic Parkinson’s Disease
Sabine Hilfiker · Rutgers, The State University of New Jersey
2021 · research · Therapeutic Pipeline Program
Using Ketamine to Treat Depression in Parkinson’s Disease
Sophie Holmes · Yale University
2021 · research · Expanding Biological Understanding of PD
Illuminating the Dark Genome of Parkinson’s Disease
Edward A. Fon · McGill University
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Preclinical Studies of Compounds that Block Alpha-synuclein Aggregation by Antagonizing the Sigma-2 Receptor
Mary E. Hamby · Cognition Therapeutics, Inc
2021 · research · Fall 2021 RFP: Outcome Measures
Development and Validation of a Sensitive Method for Measuring PINK
Fabienne C. Fiesel · Mayo Clinic
2021 · research · Research Grant
Exploring the Protective Effect of Modulating Brain Cells’ Electrical Activity in Parkinson’s Disease
Cedric Bardy · Flinders University
2021 · research · Research Grant
Comparing the Effectiveness of Two Imaging Methods for Monitoring the Progression of Parkinson’s Disease
Daniel Huddleston · Emory University
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Preclinical Development of Immune-inhibiting Small Molecules as Therapeutics for Parkinson’s Disease
Erik M. Schwiebert · Discoverybiomed, Inc.
2021 · research · Therapeutic Pipeline Program
Directed Evolution of Tailor-Made Molecular Chaperones
Shu-Ou Shan · California Institute of Technology
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Modulation of Glycine for the Treatment of Parkinson’s Disease
Philippe Huot · Montreal Neurological Institute and Hospital
2021 · research · Aligning Science Across Parkinson's
Role of Enteroendocrine Cells in the Origin of Parkinson's Pathology
William C. Mobley · University of California San Diego
2021 · research · Outcome Measures
Protective Effect of Immune Gene Subtype in Parkinson’s Disease
Emmanuel Mignot · Stanford Medicine
2021 · research · Aligning Science Across Parkinson's
Gut-to-brain Circuit Contributions to Parkinson-like Phenotypes in Disease Models
Viviana Gradinaru · California Institute of Technology
2021 · research · Research Grant
Tagging Genes Associated with Parkinson’s Disease Using the Gene-editing CRISPR Tool
Thomas M. Durcan · McGill University
2021 · research · Research Grant
Developing a Diagnostic Test to Detect the Signature Scent of Parkinson’s Disease
Paul Feinstein · Hunter College
2021 · research · Target Advancement Program
Pre-clinical Validation of a Novel Target for Dyskinesia Induced by Levodopa
Kimberly R. Thompson · Maplight Therapeutics
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease
Gergely Toth · Cantabio Pharmaceuticals
2021 · research · PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development
San Antonio Ligand Consortium (SALC)
Peter Thornton Fox · The University of Texas at San Antonio Health Science Center